Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
10 studies found for:    pulmonary alveolar proteinosis
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
Conditions: Pulmonary Alveolar Proteinosis;   Primary Disease
Intervention: Drug: rituximab
2 Recruiting Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)
Condition: Autoimmune Pulmonary Alveolar Proteinosis
Intervention: Drug: GM-CSF
3 Completed Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Condition: Hereditary Pulmonary Alveolar Proteinosis
Intervention: Drug: Leukine
4 Enrolling by invitation Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)
Condition: Pulmonary Alveolar Proteinosis
Interventions: Drug: GM-CSF [Leukine (Sargramostim)];   Procedure: WLL
5 Unknown  GM-CSF in Patients With Pulmonary Alveolar Proteinosis
Condition: Pulmonary Alveolar Proteinosis
Intervention: Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)
6 Recruiting Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.
Condition: Pulmonary Alveolar Proteinosis
Interventions: Drug: rhGM-CSF;   Procedure: Whole Lung Lavage(WLL)
7 Recruiting Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT
Condition: Pulmonary Alveolar Proteinosis (PAP).
Interventions: Device: MRI;   Radiation: Research CT if clinical one is complete before the pre lavage
8 Recruiting Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Conditions: Anticytokine Autoantibody-Associated Diseases;   Disseminated Non-Tuberculous Mycobacteria;   Chronic Mucocutaneous Candidiasis;   Pulmonary Alveolar Proteinosis (PAP)
Intervention: Drug: Rituximab/Rituxan
9 Recruiting Natural History Study of GATA2 Deficiency and Related Disorders
Conditions: Myelodysplasia;   Monocytopenia;   B Cell Lymphopenia;   NK Cell Deficiency;   Warts
Intervention:
10 Recruiting Epidemiology of Surfactant Protein-B Deficiency
Conditions: Lung Diseases;   Respiratory Distress Syndrome, Newborn;   Pulmonary Surfactants
Intervention:

Indicates status has not been verified in more than two years